Advertisement

Journal of Neuro-Oncology

, Volume 100, Issue 3, pp 475–479 | Cite as

Tonsillar pseudotumor: complications of chronically-administered temozolomide

  • Kathleen Grisdale
  • Melesa Ritterhouse
  • Kathy Hunter
  • Michelle D. Williams
  • Morris D. Groves
Case Report

Abstract

The current standard of care for patients with Glioblastoma multiforme (GBM) is surgery, followed by radiation in combination with Temozolomide (TMZ), followed by adjuvant TMZ. The most appropriate length of treatment of adjuvant TMZ after the completion of radiation is unclear. We present the case of a 45 year old female with GBM who received adjuvant TMZ on an experimental study for 24 1-month cycles (150 mg/M2 7 days on/7 days off continuously-a higher TMZ dose than standard). After 24 months on study she was stable without GBM regrowth, but presented with a right tonsil and pharynx mass consistent with a new primary malignancy. Tonsillar biopsy was positive for Epstein–Barr virus, Cytomegalovirus and Herpes Simplex Virus, but no tumor. This case highlights the risks and possible complications of immunosuppression associated with long term TMZ use.

Keywords

Glioblastoma multiforme Temozolomide Epstein–Barr Virus Cytomegalovirus Herpes Simplex Virus 

References

  1. 1.
    Stupp R, Mason WP et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMedGoogle Scholar
  2. 2.
    Pollack A (2009) Considering longer chemotherapy. The New York Times, New YorkGoogle Scholar
  3. 3.
    Stupp R, Hegi ME et al (2009) Effects of radiotherapy with concomitant with adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466CrossRefPubMedGoogle Scholar
  4. 4.
    Perry JR, Rizek P et al (2008) Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue” approach. Cancer 113(8):2152–2157CrossRefPubMedGoogle Scholar
  5. 5.
    Yung WK, Prados MD et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17(9):2762–2771PubMedGoogle Scholar
  6. 6.
    Mrugala MM, Johnston SK et al (2008) Cytopenias in patients with newly diagnosed high-grade gliomas receiving radiation and temozolomide-who is at risk? Neuro Oncol 10(6):1120 (abstract P156)Google Scholar
  7. 7.
    Gerber DE, Grossman SA et al (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9(1):47–52CrossRefPubMedGoogle Scholar
  8. 8.
    Su YB, Sohn S et al (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22(4):610–616CrossRefPubMedGoogle Scholar
  9. 9.
    Georgescu G, Isola IM et al (2008) Disseminated salmonellosis in a patient treated with temozolomide. J Infect 57(5):414–415CrossRefPubMedGoogle Scholar
  10. 10.
    Hau P, Koch D et al (2007) Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 68(9):688–690CrossRefPubMedGoogle Scholar
  11. 11.
    Binello E, Germano IM (2009) Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology? J Neurooncol 94(1):145–148CrossRefPubMedGoogle Scholar
  12. 12.
    Tamm M (1999) The lung in the immunocomprised patients. Infectious complications part 2. Respiration 66(3):199–207CrossRefPubMedGoogle Scholar
  13. 13.
    Snoeck R (2000) Antiviral therapy of herpes simplex. Int J Antimicrob Agents 16(2):157–159CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Kathleen Grisdale
    • 1
  • Melesa Ritterhouse
    • 1
  • Kathy Hunter
    • 1
  • Michelle D. Williams
    • 2
  • Morris D. Groves
    • 1
  1. 1.Department of Neuro-OncologyThe University of Texas MD Anderson Texas Cancer CenterHoustonUSA
  2. 2.Department of PathologyThe University of Texas MD Anderson Texas Cancer CenterHoustonUSA

Personalised recommendations